IL13 and breast carcinoma: As shown in Figure 3A the BLT is very potent with and IC50 of 0.019 nM on the EGF+IL-13+ cell line MDA-MB-231 (breast carcinoma cell line) and has greater activity than its monospecific counterparts in our in vitro proliferation screening assay.